Daiichi Sankyo Company, Limited

Masaki Kiga

Kenji Yoshikawa

Yuko Yamamoto

Yoshiko Kagoshima

Yasuyuki Takeda

Yuichi Tominaga

Yoshito Hamada

Ryoichi Tanaka

Provided are: a method of predicting sensitivity to a molecularly targeted drug; a method of selecting a patient who is determined to have high responsiveness to administration of a drug; and a reagent to be used in these methods. Specifically, provided are: a method of predicting responsiveness to cancer disease treatment with a compound that inhibits a mitogen-activated protein kinase (hereinafter abbreviated as MAPK) signaling pathway, the method including using a biological sample derived from a cancer patient, measuring whether or not &#x3b2;-catenin contained in the biological sample has at least one kind of mutation selected from the group consisting of (i) an active mutation and (ii) a substitution mutation of an asparagine residue to a serine residue at position 287; a method of selecting a patient to be subjected to cancer disease treatment with the compound; a method of treating a cancer disease, the method including administering the compound to the patient selected by the above-mentioned method; and a reagent to be used in these methods.

Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R, G, T, Y, Y, Y, and Yare as defined herein.

Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

Growing community of inventors

Shinagawa-ku, Japan

Masaki Kiga